{"id":"artesunate-mefloquine-piperaquine","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Neuropsychiatric effects (mefloquine-related)"}]},"_chembl":{"chemblId":"CHEMBL361497","moleculeType":"Small molecule","molecularWeight":"384.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Artesunate is a fast-acting artemisinin derivative that rapidly reduces parasite biomass by generating reactive oxygen species. Mefloquine and piperaquine are quinoline-based antimalarials that inhibit heme polymerization and parasite protein synthesis. The triple combination leverages different mechanisms to prevent resistance development and provide synergistic efficacy against Plasmodium species.","oneSentence":"This combination of three antimalarial agents works by disrupting parasite metabolism and preventing drug resistance through multiple complementary mechanisms of action.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:43:01.442Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated malaria caused by Plasmodium falciparum"},{"name":"Malaria in areas with artemisinin or partner drug resistance"}]},"trialDetails":[{"nctId":"NCT03923725","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-09-01","conditions":"Plasmodium Falciparum Malaria (Uncomplicated)","enrollment":2583},{"nctId":"NCT03939104","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-06-30","conditions":"Plasmodium Falciparum Malaria (Uncomplicated)","enrollment":103},{"nctId":"NCT01640587","phase":"NA","title":"Compare the Effectiveness Between Existing Treatment and New Treatment","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2013-11","conditions":"P. Falciparum Malaria","enrollment":76},{"nctId":"NCT05052502","phase":"NA","title":"Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand","status":"UNKNOWN","sponsor":"University of California, San Francisco","startDate":"2020-11-01","conditions":"Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria","enrollment":49118},{"nctId":"NCT01054248","phase":"PHASE3","title":"Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-02-16","conditions":"Malaria","enrollment":511},{"nctId":"NCT02653898","phase":"PHASE4","title":"Malaria Elimination Pilot Study in Military Forces in Cambodia","status":"UNKNOWN","sponsor":"Armed Forces Research Institute of Medical Sciences, Thailand","startDate":"2016-01","conditions":"Malaria, Parasitic Diseases","enrollment":1050},{"nctId":"NCT02612545","phase":"PHASE1","title":"Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-11-20","conditions":"Acute Falciparum Malaria","enrollment":216},{"nctId":"NCT02453308","phase":"PHASE2, PHASE3","title":"A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-08","conditions":"Malaria, Falciparum","enrollment":1110},{"nctId":"NCT02974348","phase":"PHASE3","title":"Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa","status":"COMPLETED","sponsor":"University of Bamenda","startDate":"2013-01","conditions":"Drug Resistant Malaria Due to Plasmodium Falciparum","enrollment":300},{"nctId":"NCT02792816","phase":"","title":"Molecular Surveillance of Artemisinin Resistance Malaria in Myanmar","status":"COMPLETED","sponsor":"Department of Medical Research, Lower Myanmar","startDate":"2009-06","conditions":"Drug Resistance, Plasmodium Falciparum Malaria","enrollment":550},{"nctId":"NCT00852423","phase":"PHASE3","title":"Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2010-06","conditions":"Malaria in Pregnancy","enrollment":3428},{"nctId":"NCT01350856","phase":"PHASE4","title":"Tracking Resistance to Artemisinin (TRAC)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2011-05","conditions":"Falciparum Malaria","enrollment":1700},{"nctId":"NCT00373607","phase":"PHASE3","title":"Efficacy and Safety of Dihydroartemisinin/Piperaquine (Artekin®) for the Treatment of Uncomplicated Malaria in Peru","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2003-07","conditions":"Malaria","enrollment":522},{"nctId":"NCT00902811","phase":"PHASE4","title":"Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria","status":"UNKNOWN","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2008-12","conditions":"Uncomplicated Falciparum Malaria","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Artesunate-mefloquine+piperaquine","genericName":"Artesunate-mefloquine+piperaquine","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination of three antimalarial agents works by disrupting parasite metabolism and preventing drug resistance through multiple complementary mechanisms of action. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria in areas with artemisinin or partner drug resistance.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}